Curis Management
Management criteria checks 3/4
Curis' CEO is Jim Dentzer, appointed in Sep 2018, has a tenure of 5.58 years. total yearly compensation is $1.66M, comprised of 38.1% salary and 61.9% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $91.32K. The average tenure of the management team and the board of directors is 4.7 years and 9.7 years respectively.
Key information
Jim Dentzer
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 38.1% |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.7yrs |
| Board average tenure | 9.7yrs |
Recent management updates
Recent updates
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 03
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Dec 26We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Apr 19Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?
Jan 02Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Sep 16Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study
Aug 18Curis: Asymmetric Risk And Reward
Jul 17Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation
Mar 28Checking In On Curis
Dec 15Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth
Dec 04We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth
Aug 29Curis Inc.: Revisiting CA-4948 After Q2 Update
Aug 25Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33
Mar 19Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year
Feb 17
Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition
Dec 23Curis prices equity offering at $5.75/share
Dec 09Curis skyrockets 141% on encouraging CA-4948 data in leukemia
Dec 08What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition
Dec 03Curis, National Cancer Institute in development pact for anti-cancer agent
Nov 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$634k | -US$47m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$3m | US$615k | -US$57m |
| Sep 30 2022 | n/a | n/a | -US$59m |
| Jun 30 2022 | n/a | n/a | -US$57m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$3m | US$590k | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$545k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$31m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$510k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | n/a | n/a | -US$30m |
| Mar 31 2019 | n/a | n/a | -US$32m |
| Dec 31 2018 | US$2m | US$479k | -US$33m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$43m |
| Mar 31 2018 | n/a | n/a | -US$48m |
| Dec 31 2017 | US$2m | US$443k | -US$53m |
Compensation vs Market: Jim's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Dentzer (56 yo)
5.6yrs
Tenure
US$1,662,978
Compensation
Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.6yrs | US$1.66m | 0.10% $ 91.3k | |
| CFO and Principal Financial & Accounting Officer | 1.7yrs | US$1.01m | 0.011% $ 9.7k | |
| Chief Development Officer | less than a year | US$1.04m | 0% $ 0 | |
| Vice President of Technology Management & Intellectual Property | 15.6yrs | US$413.39k | no data | |
| VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Clinical Development | 4.7yrs | no data | no data |
4.7yrs
Average Tenure
56.5yo
Average Age
Experienced Management: CRIS's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.6yrs | US$1.66m | 0.10% $ 91.3k | |
| Independent Chairman of the Board | 24.2yrs | US$158.70k | 0.022% $ 19.6k | |
| Independent Director | 13.8yrs | US$123.70k | 0.024% $ 21.6k | |
| Independent Director | 20.4yrs | US$126.20k | 0.024% $ 21.1k | |
| Independent Director | 2.3yrs | US$106.20k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$103.70k | 0% $ 0 |
9.7yrs
Average Tenure
65.5yo
Average Age
Experienced Board: CRIS's board of directors are considered experienced (9.7 years average tenure).